FCBT
TVRD

First Citizens Bank & Trust’s Tvardi Therapeutics TVRD Stock Holding History

First Citizens Bank & Trust’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-437
Closed -$143K – 402
2022
Q2 		$143K Sell
437
-124
-22% -$43.5K 0.01% 389
2022
Q1 		$246K Buy
+561
New +$230K 0.01% 359

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Citizens Bank & Trust's TVRD Position: Q3 2022 in Review

First Citizens Bank & Trust sold out of Tvardi Therapeutics (TVRD) in Q3 2022, closing a stake of 437 shares — an estimated $143K sold.

First Citizens Bank & Trust first reported a position in TVRD in Q1 2022 and held it in 2 quarters. The position peaked at $246K in Q1 2022. 165 funds tracked by Wall St. Rank hold TVRD as of Q3 2022.

  • First Citizens Bank & Trust reported no remaining Tvardi Therapeutics position as of Q3 2022 after selling out during the quarter.
  • First Citizens Bank & Trust sold 437 Tvardi Therapeutics shares in Q3 2022, an estimated $143K.
  • First Citizens Bank & Trust first reported a position in Tvardi Therapeutics in Q1 2022 and held it in 2 quarters.
  • First Citizens Bank & Trust's Tvardi Therapeutics position peaked at $246K in Q1 2022.
  • 165 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2022.

Based on First Citizens Bank & Trust's 13F filing for Q3 2022, filed 20 Oct 2022.